ff US Biz (32% of Sales): The Management expects the US sales to report strong growth in 2HFY19E led by new launches (gLevothyroxine & gRanexa), pick-up in gTamiflu/ Cephalosporin sales led by upcoming flu season and ramp-up in Solosec sales. With lower sales in 1HFY19, LPC expects its US sales at lower end of earlier guidance of US$800-850mn in FY19E. On positive note, the Management indicated that pricing pressure has been moderated in the US due to exit of MNCs in unviable products. Notably, gLevothyroxine launch is postponed to 4QFY19 vs. earlier guidance of 3QFY19. ff Women's care brand i.e. Solosec contributed US$3mn to sales, LPC aims to achieve 15-20%...